Delivery Order SPE2DB24D2213-SPE2DB25FGXFE
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,545.48 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. This is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, awarded on July 18, 2025, with no set-aside designation. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials, with a contract ceiling value of $1,703.81. This is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and represents a non-competitive set-aside award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor and critical vendor...
- The Defense Logistics Agency awarded a delivery order valued at $3,804.40 to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 ml) in 3 ml vials. The contract is a firm fixed price delivery order issued on July 18, 2025, with an ultimate completion date of July 21, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. No set-aside designation was used for...
- The Defense Logistics Agency awarded a $66,741.92 delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 mL) vials on July 18, 2025, with an ultimate completion date of July 21, 2025. This is a firm fixed-price, non-set-aside contract with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml vials, with a ceiling value of $3,578.75. This competitively awarded, firm fixed-price delivery order was issued on July 18, 2025, with an ultimate completion date of July 21, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The Defense Logistics Agency (DLA) awarded a $12,891.92 delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml vials, with an ultimate completion date of July 21, 2025. This competitive award, issued on July 18, 2025, utilizes firm fixed pricing and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.9 million through December 2026. The place of...
- The Defense Logistics Agency awarded a $15,380.88 delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 mL) in 3 mL vials. This contract, awarded on July 18, 2025, with an ultimate completion date of July 21, 2025, is structured as a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a $7,556.52 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Ozempic 2 mg/dose (8 mg/3 ml) in 3 ml vials, with performance completion targeted for July 21, 2025. This delivery order represents a firm fixed-price, non-set-aside competitive award executed through AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The pharmaceutical product will be delivered to the company's...
- The Defense Logistics Agency awarded a $34,710.25 delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic 2 mg/dose (8 mg/3 ml) 3ml vials under a firm fixed-price contract. The award, issued on July 18, 2025, with an ultimate completion date of July 21, 2025, represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement needs, particularly...
- The Defense Logistics Agency awarded a $4,177.64 delivery order to AmerisourceBergen Drug Corp for Ozempic 1 mg/dose (4 mg/3 mL) 3 mL vials under a firm fixed-price contract, with an ultimate completion date of July 21, 2025. This award represents a non-set-aside, competitively awarded delivery order executed through AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026 that...
- SPE2DB24D2213Indefinite Delivery Contract
- SPE2DB24D2213-SPE2DB25FGXFEDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,782.72 to AmerisourceBergen Drug Corp for the supply of Ozempic 1 mg/dose (4 mg/3 mL) in 3 mL vials. This firm fixed price delivery order, issued on July 18, 2025, with completion expected by July 21, 2025, was awarded without a set-aside designation through competitive procurement. The contract represents a fulfillment under AmerisourceBergen's existing indefinite delivery contract (IDC) with DLA Troop Support Medical (SPE2DX), a $1 billion global pharmaceutical prime vendor agreement running through December 2026. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order reflects the ongoing supply chain operations supporting the Defense Health Agency, U.S. Coast Guard, and other federal military and veteran healthcare systems. AmerisourceBergen, a major pharmaceutical distributor, supplies a comprehensive portfolio of medications and medical commodities through its DLA contracts, including specialty pharmaceuticals, vaccines, and medical devices across multiple therapeutic domains. The award demonstrates the contractor's continued capability to meet federal procurement requirements for critical medications, including diabetes treatments such as Ozempic, which support military healthcare readiness and operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.8k | 7/18/25 |